ALTERTOX

Over the past few weeks, we’ve explored 𝗡𝗲𝘄 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝗠𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝗶𝗲𝘀 (#𝗡𝗔𝗠𝘀) as part of our ALTERTOX 𝗡𝗔𝗠𝘀 𝗞𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲-𝗦𝗵𝗮𝗿𝗶𝗻𝗴 𝗖𝗮𝗺𝗽𝗮𝗶𝗴𝗻—looking at how they’re transforming research, advancing animal welfare, and providing innovative alternatives to traditional testing. This campaign was brought to life by the contributions of this incredible team: 🖊️ 𝗪𝗿𝗶𝘁𝗲𝗿: Monicah Kirathi – Translating complex science into relatable, digestible content.  🎨 𝗚𝗿𝗮𝗽𝗵𝗶𝗰 𝗗𝗲𝘀𝗶𝗴𝗻𝗲𝗿: Aurélia Boige – Designing visuals that connect with the story we’re telling.  🔎 𝗥𝗲𝘃𝗶𝗲𝘄𝗲𝗿: Leonie Mueller – Ensuring scientific accuracy and clarity. 💬 "𝙒𝙚’𝙫𝙚 𝙚𝙣𝙟𝙤𝙮𝙚𝙙 𝙚𝙭𝙥𝙡𝙤𝙧𝙞𝙣𝙜 𝙉𝘼𝙈𝙨 𝙬𝙞𝙩𝙝 𝙮𝙤𝙪 𝙖𝙣𝙙 𝙝𝙖𝙫𝙚 𝙗𝙚𝙚𝙣 𝙞𝙣𝙨𝙥𝙞𝙧𝙚𝙙 𝙗𝙮 𝙩𝙝𝙚 𝙘𝙤𝙣𝙫𝙚𝙧𝙨𝙖𝙩𝙞𝙤𝙣𝙨 𝙨𝙥𝙖𝙧𝙠𝙚𝙙 𝙗𝙮 𝙩𝙝𝙞𝙨 𝙘𝙖𝙢𝙥𝙖𝙞𝙜𝙣. 𝙏𝙝𝙖𝙣𝙠 𝙮𝙤𝙪 𝙛𝙤𝙧 𝙚𝙣𝙜𝙖𝙜𝙞𝙣𝙜, 𝙨𝙝𝙖𝙧𝙞𝙣𝙜 𝙮𝙤𝙪𝙧 𝙞𝙣𝙨𝙞𝙜𝙝𝙩𝙨 𝙖𝙣𝙙 𝙟𝙤𝙞𝙣𝙞𝙣𝙜 𝙩𝙝𝙚 𝙙𝙞𝙖𝙡𝙤𝙜𝙪𝙚!" We’re wrapping up this series with our 𝗳𝗶𝗻𝗮𝗹 𝗤&𝗔 𝗽𝗼𝘀𝘁 𝗻𝗲𝘅𝘁 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆! ❓ 𝗚𝗼𝘁 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 𝘆𝗼𝘂’𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗮𝗱𝗱𝗿𝗲𝘀𝘀𝗲𝗱? Drop them in the comments below. 👇 #NAMs #ScienceCommunication #3Rs #TeamSpotlight #AlternativesToAnimalTesting #Altertox 

 ✨ 𝗥𝗲𝗰𝗮𝗽 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 PEPPER 𝗦𝗬𝗠𝗣𝗢𝗦𝗜𝗨𝗠 ✨ Last week, we joined the Pepper Anniversary Congress which brought 𝗽𝘂𝗯𝗹𝗶𝗰 𝗮𝘂𝘁𝗵𝗼𝗿𝗶𝘁𝗶𝗲𝘀, 𝗽𝗼𝗹𝗶𝗰𝘆𝗺𝗮𝗸𝗲𝗿𝘀, 𝗮𝗻𝗱 𝗿𝗶𝘀𝗸 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 from key institutions such as: French Ministries  European Commission DG ENV  Joint Research Center (DG JRC)  Bundesinstitut für Risikobewertung (German Federal Institute for Risk Assessment)  The Dutch Ministry  European Chemicals Agency (ECHA)   The discussions focused on much more than the achievements of the 𝗣𝗲𝗽𝗽𝗲𝗿 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 itself. The real emphasis was on the why and how of validation: 👉 𝗪𝗵𝘆 𝗱𝗼 𝘄𝗲 𝗻𝗲𝗲𝗱 𝗳𝗮𝘀𝘁𝗲𝗿 𝗮𝗻𝗱 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗺𝗲𝘁𝗵𝗼𝗱𝘀?  👉 𝗛𝗼𝘄 𝗰𝗮𝗻 𝘄𝗲 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝘁𝗵𝗲 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀?  👉 𝗪𝗵𝗮𝘁 𝗿𝗼𝗹𝗲 𝗱𝗼𝗲𝘀 𝗰𝗿𝗼𝘀𝘀-𝘀𝗲𝗰𝘁𝗼𝗿 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗽𝗹𝗮𝘆 𝗶𝗻 𝗮𝗱𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝘁𝗵𝗲𝘀𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀? A key takeaway?  Validation efforts must evolve through pragmatic, policy-driven approaches and strengthened partnerships. There’s immense potential in public-private partnerships, improved governance models, strategic prioritization, and aligning validation efforts of endocrine disruptors with policy needs. We’re excited to build on the shared insights. ---- #PepperSymposium #EndocrineDisruptors #InnovationInScience #PublicHealth #ScientificCollaboration #Validation #EUHealth #HealthProtection  ---- Ofelia Bercaru / Cécile Lemaître / Bob Diderich  / Maurice Whelan / Philippe Hubert  / Pascal Sanders  / Matthew Burbank  / Gregory Lemkine  / Joëlle Rüegg  

We’re on site at the PEPPER 𝗦𝗬𝗠𝗣𝗢𝗦𝗜𝗨𝗠: “𝙀𝙣𝙙𝙤𝙘𝙧𝙞𝙣𝙚 𝘿𝙞𝙨𝙧𝙪𝙥𝙩𝙤𝙧𝙨: 𝘼𝙘𝙘𝙚𝙡𝙚𝙧𝙖𝙩𝙞𝙣𝙜 𝙈𝙚𝙩𝙝𝙤𝙙𝙨 𝙑𝙖𝙡𝙞𝙙𝙖𝙩𝙞𝙤𝙣 𝙩𝙤 𝙄𝙢𝙥𝙧𝙤𝙫𝙚 𝙊𝙪𝙧 𝙋𝙧𝙤𝙩𝙚𝙘𝙩𝙞𝙤𝙣, 5 𝙔𝙚𝙖𝙧𝙨 𝙤𝙛 𝘼𝙘𝙝𝙞𝙚𝙫𝙚𝙢𝙚𝙣𝙩𝙨 𝙖𝙣𝙙 𝙋𝙚𝙧𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚𝙨 𝙤𝙛 𝙩𝙝𝙚 𝙋𝙚𝙥𝙥𝙚𝙧 𝙋𝙡𝙖𝙩𝙛𝙤𝙧𝙢.”  We’re happy to be part of this important event, where 𝗼𝘃𝗲𝗿 20 𝗲𝘀𝘁𝗲𝗲𝗺𝗲𝗱 𝘀𝗽𝗲𝗮𝗸𝗲𝗿𝘀—including policymakers, risk assessment agencies, and experts from both public and private laboratories—are leading open and pragmatic discussions that are shaping the future of our understanding and protection against 𝗲𝗻𝗱𝗼𝗰𝗿𝗶𝗻𝗲 𝗱𝗶𝘀𝗿𝘂𝗽𝘁𝗼𝗿𝘀. A huge thank you to the organisers, speakers, participants, and partners for making this symposium a powerful catalyst for change. 𝗞𝗲𝗲𝗽 𝗽𝗼𝘀𝘁𝗲𝗱 𝘁𝗼 𝗴𝗲𝘁 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗮𝗻𝗱 𝘁𝗮𝗸𝗲-𝗵𝗼𝗺𝗲 𝗺𝗲𝘀𝘀𝗮𝗴𝗲𝘀 𝗶𝗻 𝗮 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗽𝗼𝘀𝘁. #PepperSymposium #EndocrineDisruptors #InnovationInScience #PublicHealth #ScientificCollaboration #EventCommunication #DigitalCommunication #DigitalStrategy #HealthProtection

🚨𝗘𝗣𝗔𝗔 3𝗥𝘀 𝗦𝘁𝘂𝗱𝗲𝗻𝘁 𝗚𝗿𝗮𝗻𝘁𝘀 2025: 𝗖𝗮𝗹𝗹 𝗳𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀 🚨  The 2025 EPAA European Partnership for Alternative Approaches 3𝗥𝘀 𝗦𝘁𝘂𝗱𝗲𝗻𝘁 𝗚𝗿𝗮𝗻𝘁𝘀 are now 𝗼𝗽𝗲𝗻 𝗳𝗼𝗿 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀! These grants support students and young scientists working on 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝘁𝗼 𝗮𝗻𝗶𝗺𝗮𝗹 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 to attend a high-profile scientific event dedicated to the #3Rs (Replacement, Reduction, Refinement).  💡 𝗪𝗵𝗮𝘁’𝘀 𝗼𝗻 𝗼𝗳𝗳𝗲𝗿?   The EPAA is offering 2 𝗳𝘂𝗹𝗹 𝗴𝗿𝗮𝗻𝘁𝘀 𝗼𝗳 €1,000 each to participate in the following events.   💠 MPS World Summit 2025 (Brussels, Belgium, June 9-13) - Application deadline 14/02/2025 💠 Society of Environmental Toxicology and Chemistry (SETAC) 2025 (Vienna, Austria, May 11-15) - Application deadline 14/02/2025 💠 EUROTOX Congress 2025 (Athens, Greece, September 14-17) - Application deadline 15/05/2025  These grants cover event 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻, 𝘁𝗿𝗮𝘃𝗲𝗹, and 𝗮𝗰𝗰𝗼𝗺𝗺𝗼𝗱𝗮𝘁𝗶𝗼𝗻 expenses (based on receipts).  💡 𝗪𝗵𝗼 𝗰𝗮𝗻 𝗮𝗽𝗽𝗹𝘆?  💠 Applicants must be 𝗯𝗮𝘀𝗲𝗱 𝗶𝗻 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 27 𝗘𝗨 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 or the 𝗨𝗞 (citizenship can be from anywhere). 💠 Applicants must have 𝗴𝗿𝗮𝗱𝘂𝗮𝘁𝗲𝗱 𝘄𝗶𝘁𝗵 𝗮 𝗕𝗦𝗰 (or equivalent, with at least 180 ECTS credits) by the time of application, but 𝗰𝗮𝗻𝗻𝗼𝘁 𝗵𝗮𝘃𝗲 𝗮 𝗱𝗼𝗰𝘁𝗼𝗿𝗮𝗹 𝗱𝗲𝗴𝗿𝗲𝗲. 💠 Applicants must still be considered 𝗳𝘂𝗹𝗹-𝘁𝗶𝗺𝗲 𝘀𝘁𝘂𝗱𝗲𝗻𝘁𝘀 𝗼𝗿 𝘆𝗼𝘂𝗻𝗴 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 (𝘂𝗻𝗱𝗲𝗿 35 𝘆𝗲𝗮𝗿𝘀 𝗼𝗹𝗱) at the time of application. 💠 Young scientists employed by industry are 𝗻𝗼𝘁 𝗲𝗹𝗶𝗴𝗶𝗯𝗹𝗲 to apply. 💠 No other funding or reimbursement for the same event from any other entity is allowed. 🔗 𝗛𝗼𝘄 𝘁𝗼 𝗮𝗽𝗽𝗹𝘆:   For full details on the eligibility criteria and submission guidelines, visit the website: https://lnkd.in/dnsyVUrA 

⭐ 𝗦𝘂𝗰𝗰𝗲𝘀𝘀 𝗦𝘁𝗼𝗿𝗶𝗲𝘀 𝗼𝗳 𝗡𝗔𝗠𝘀 𝗜𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗧𝗼𝘅𝗶𝗰𝗼𝗹𝗼𝗴𝘆 ⭐  The integration of #NAMs is revolutionizing drug development, offering predictive, efficient, and humane alternatives to traditional animal testing. These innovations are not only enhancing our ability to assess drug safety and efficacy but are also reducing costs and accelerating time-to-market. Here are three 𝗻𝗼𝘁𝗲𝘄𝗼𝗿𝘁𝗵𝘆 𝗲𝘅𝗮𝗺𝗽𝗹𝗲𝘀 of NAMs successfully implemented in clinical practice and drug development: 🔬𝗛𝘂𝗺𝗮𝗻-𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗻𝗴 𝗖𝗵𝗶𝗽 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 Scientists at The Hebrew University of Jerusalem have made groundbreaking strides by using a human-simulating chip to develop a cancer drug, eliminating the need for animal testing. This chip mimics human organ functions, allowing researchers to test drug effects on the kidney, liver, and heart. By combining cisplatin (a cancer drug) with empagliflozin (a diabetes medication), they significantly reduced fat buildup in the liver. This breakthrough accelerates drug development and improves testing accuracy. The team is now advancing the drug combination toward clinical trials, patent submission, and FDA approval. 🚀 🧠3𝗗 𝗕𝗹𝗼𝗼𝗱-𝗕𝗿𝗮𝗶𝗻 𝗕𝗮𝗿𝗿𝗶𝗲𝗿 𝗠𝗼𝗱𝗲𝗹 𝗳𝗼𝗿 𝗚𝗹𝗶𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮 𝗧𝗿𝗶𝗮𝗹𝘀 At Roche, researchers have successfully utilized a 3D blood-brain barrier- glioblastoma model to optimize the starting dose for a first-in-human (FIH) trial of T-cell bispecific constructs. This model offers a more accurate representation of human physiology, improving the safety and efficacy of clinical trials. The translational strategy was presented to the FDA and Danish Health Authority, receiving regulatory approval in Europe, the USA, Canada, and Australia. 🌍💡 💉𝗧𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗳𝗿𝗼𝗺 𝗜𝗻 𝗩𝗶𝘃𝗼 𝘁𝗼 𝗜𝗻 𝗩𝗶𝘁𝗿𝗼 𝗣𝗼𝘁𝗲𝗻𝗰𝘆 𝗔𝘀𝘀𝗮𝘆𝘀 𝗳𝗼𝗿 𝗙𝗲𝗿𝘁𝗶𝗹𝗶𝘁𝘆 𝗛𝗼𝗿𝗺𝗼𝗻𝗲𝘀  For decades, fertility hormones such as Follicle Stimulating Hormone (FSH) have been evaluated using the Steelman-Pohley in vivo bioassay for market batch release. Merck has pioneered an in vitro potency assay as a viable alternative to this traditional approach. After extensive testing and validation, Merck demonstrated that the in vitro assay could effectively replace the in vivo bioassay, offering similar performance in assessing hormone activity and detecting molecular changes. This transition was supported by an in-depth structure-activity relationship (SAR) analysis. The new in vitro method has since been approved in numerous countries, with continued global adoption. This achievement underscores Merck's dedication to advancing the #3Rs principles —reducing animal testing, improving release timelines, and ensuring the highest standards in drug quality control. 💊 Do you know of any other successful NAMs implementations in toxicology? Share your stories and insights in the comments below! 👇 

🌍 𝗔𝗹𝘁𝗲𝗿𝘁𝗼𝘅 𝗖𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗲𝘀 𝗘𝗛𝗘𝗡'𝘀 𝗙𝗶𝗻𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴! We were honored to attend the 𝗘𝗛𝗘𝗡 (𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗛𝘂𝗺𝗮𝗻 𝗘𝘅𝗽𝗼𝘀𝗼𝗺𝗲 𝗡𝗲𝘁𝘄𝗼𝗿𝗸) 𝗳𝗶𝗻𝗮𝗹 𝗺𝗲𝗲𝘁𝗶𝗻𝗴, 𝗵𝗼𝘀𝘁𝗲𝗱 𝗯𝘆 𝘁𝗵𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗼𝗺𝗺𝗶𝘀𝘀𝗶𝗼𝗻. 🌟 This milestone event highlighted 9 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝘀, supported with a total investment of €100𝗠—a testament to Europe’s commitment to environmental and health innovation. 🚀 𝗧𝗵𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗼𝗺𝗺𝗶𝘀𝘀𝗶𝗼𝗻 (𝗗𝗚 𝗥𝗧𝗗 & 𝗗𝗚 𝗘𝗡𝗩) is supporting bold solutions for some of the most pressing challenges we face today. 🔎 𝗪𝗵𝘆 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: It’s all interconnected: ✨ Supporting 𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁 𝗩𝗼𝗻 𝗗𝗲𝗿 𝗟𝗲𝘆𝗲𝗻'𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 & 𝗘𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁 𝗴𝗼𝗮𝗹𝘀 ✨ Aligning with EU priorities like 𝘇𝗲𝗿𝗼 𝗽𝗼𝗹𝗹𝘂𝘁𝗶𝗼𝗻 𝗮𝗺𝗯𝗶𝘁𝗶𝗼𝗻, 𝗯𝗶𝗼𝗱𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆, 𝗰𝗹𝗲𝗮𝗻 𝗮𝗶𝗿, 𝗰𝗹𝗶𝗺𝗮𝘁𝗲 𝗮𝗱𝗮𝗽𝘁𝗮𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝘀𝗼𝗰𝗶𝗮𝗹 𝗳𝗮𝗶𝗿𝗻𝗲𝘀𝘀 💡 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 & 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀: The way forward lies in 𝗺𝘂𝗹𝘁𝗶𝗱𝗶𝘀𝗰𝗶𝗽𝗹𝗶𝗻𝗮𝗿𝘆 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻. By integrating insights from fields like 𝘂𝗿𝗯𝗮𝗻 𝗽𝗹𝗮𝗻𝗻𝗶𝗻𝗴, 𝗮𝗻𝘁𝗵𝗿𝗼𝗽𝗼𝗹𝗼𝗴𝘆, 𝗯𝗲𝗵𝗮𝘃𝗶𝗼𝗿𝗮𝗹 𝘀𝗰𝗶𝗲𝗻𝗰𝗲, and 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗲𝗰𝗼𝗻𝗼𝗺𝗶𝗰𝘀, we can unlock new solutions and perspectives. 🌐 📚 𝗠𝘂𝘀𝘁-𝗿𝗲𝗮𝗱𝘀 𝗳𝗿𝗼𝗺 𝗧𝗵𝗲 𝗚𝘂𝗮𝗿𝗱𝗶𝗮𝗻: 1️⃣ Air pollution and its impact on health risks : https://lnkd.in/dTsPd39i  2️⃣ Why insurance companies are taking an interest in the exposome: https://lnkd.in/gtxYsFAF 🌟 𝗡𝗲𝘅𝘁 𝘀𝘁𝗲𝗽: 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻! We’re excited to set our sights on the 𝗘𝘅𝗽𝗼𝘀𝗼𝗺𝗲 𝗠𝗼𝗼𝗻𝘀𝗵𝗼𝘁 in Washington, D.C., in 2025. Let’s build on this momentum and advance global research efforts. 🌎 Learn more: Exposome Moonshot 2025 (https://lnkd.in/ejWgUcXr)

🌟 𝗔𝗹𝘁𝗲𝗿𝘁𝗼𝘅 𝗮𝘁 𝘁𝗵𝗲 𝗜𝗻𝗮𝘂𝗴𝘂𝗿𝗮𝗹 𝗚𝗜𝗦 𝗙𝗖3𝗥 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲! 🌟 We were thrilled to participate in the inaugural conference hosted by the GIS FC3R —a pivotal event bringing together leaders in public and private research, academia, industry, and associations to advance the 3Rs (Replacement, Reduction, Refinement). 𝗔𝘀 𝗮 𝘀𝗽𝗼𝗻𝘀𝗼𝗿, 𝗔𝗹𝘁𝗲𝗿𝘁𝗼𝘅 𝗽𝗿𝗼𝘂𝗱𝗹𝘆 𝘀𝗵𝗼𝘄𝗰𝗮𝘀𝗲𝗱 𝘁𝗵𝗲 𝗧𝗔𝗧𝗔𝗯𝗼𝘅, our supplementary tool empowering researchers and animal welfare bodies to integrate 3R principles into procedural planning. 💡🐾 The event celebrated three years of FC3R’s impactful work, from high-profile projects and training resources to initiatives like AREA, the comprehensive directory of French replacement methods. We also witnessed inspiring discussions on 3R implementation strategies and applauded the winners of the FC3R 2024 Awards for their groundbreaking contributions. 🏆 Congratulations to GIS FC3R on a successful conference! We’re already looking forward to the next gathering in 2026. #3Rs #ResearchInnovation #AnimalWelfare #GISFC3R #Altertox 

🚨@𝗔𝗟𝗧𝗘𝗥𝗧𝗢𝗫 𝗡𝗔𝗠𝘀 𝗞𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲-𝘀𝗵𝗮𝗿𝗶𝗻𝗴 𝗰𝗮𝗺𝗽𝗮𝗶𝗴𝗻🚨 ⭐𝗔𝗱𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗖𝗼𝗺𝗺𝗼𝗻 𝗖𝗼𝗻𝗰𝗲𝗿𝗻𝘀 𝗮𝗯𝗼𝘂𝘁 𝗡𝗔𝗠𝘀⭐ The ongoing evolution of methodologies in toxicology has sparked intense debate within the research community, particularly concerning the 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗳𝗿𝗼𝗺 𝘁𝗿𝗮𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝗶𝗺𝗮𝗹 𝗺𝗼𝗱𝗲𝗹𝘀 𝘁𝗼 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲 𝘀𝘆𝘀𝘁𝗲𝗺𝘀. While the #3Rs principle (Replacement, Reduction, Refinement) is at the forefront of this shift, the 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝗶𝗲𝘀 𝗼𝗳 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗻𝗴 𝗻𝗼𝘃𝗲𝗹 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝘄𝗲𝗹𝗹-𝗲𝘀𝘁𝗮𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗮𝗻𝗶𝗺𝗮𝗹 𝗺𝗼𝗱𝗲𝗹𝘀 𝗿𝗲𝗺𝗮𝗶𝗻 𝗮 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗰𝗼𝗻𝗰𝗲𝗿𝗻. Advancements such as 𝗼𝗿𝗴𝗮𝗻-𝗼𝗻-𝗰𝗵𝗶𝗽 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆, 𝗰𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝘁𝗼𝘅𝗶𝗰𝗼𝗹𝗼𝗴𝘆, 𝗮𝗻𝗱 𝗶𝗻 𝘃𝗶𝘁𝗿𝗼 𝗰𝗲𝗹𝗹𝘂𝗹𝗮𝗿 𝗮𝘀𝘀𝗮𝘆𝘀 are being explored as alternatives to animal models. These systems aim to better simulate human physiology, enhance reproducibility, and reduce the ethical burden of animal testing. 𝗛𝗼𝘄𝗲𝘃𝗲𝗿, 𝗱𝗲𝘀𝗽𝗶𝘁𝗲 𝘁𝗵𝗲𝗶𝗿 𝗽𝗿𝗼𝗺𝗶𝘀𝗲, 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝘄𝗶𝗱𝗲𝗿 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 𝗽𝗲𝗿𝘀𝗶𝘀𝘁 𝗶𝗻 𝘁𝗲𝗿𝗺𝘀 𝗼𝗳 𝗽𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆, 𝗰𝗿𝗼𝘀𝘀-𝘀𝗽𝗲𝗰𝗶𝗲𝘀 𝗲𝘅𝘁𝗿𝗮𝗽𝗼𝗹𝗮𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗰𝗰𝗲𝗽𝘁𝗮𝗻𝗰𝗲. In vitro systems offer valuable insights into cellular toxicity. 𝗪𝗵𝗶𝗹𝗲 𝘁𝗵𝗲𝘆 𝗺𝗮𝘆 𝗻𝗼𝘁 𝗳𝘂𝗹𝗹𝘆 𝗿𝗲𝗽𝗹𝗶𝗰𝗮𝘁𝗲 𝘁𝗵𝗲 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆 𝗼𝗳 𝘄𝗵𝗼𝗹𝗲-𝗮𝗻𝗶𝗺𝗮𝗹 𝗺𝗼𝗱𝗲𝗹𝘀—such as metabolism and inter-organ interactions—t𝗵𝗲𝘆 𝗽𝗿𝗼𝘃𝗶𝗱𝗲 𝗮 𝗳𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗼𝘂𝗿 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗼𝗳 𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗶𝗻𝗴 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁𝘀. Similarly, 𝗰𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗼𝗱𝗲𝗹𝘀 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝘁𝗼 𝗲𝘃𝗼𝗹𝘃𝗲 𝗶𝗻 𝘀𝗼𝗽𝗵𝗶𝘀𝘁𝗶𝗰𝗮𝘁𝗶𝗼𝗻, showcasing immense potential when backed by high-quality data. 𝗧𝗵𝗲𝗶𝗿 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗿𝗼𝗹𝗲 𝗶𝗻 𝗽𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝘃𝗲 𝘁𝗼𝘅𝗶𝗰𝗼𝗹𝗼𝗴𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗮 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝘀𝗵𝗶𝗳𝘁 𝘁𝗼𝘄𝗮𝗿𝗱 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲, 𝗱𝗮𝘁𝗮-𝗱𝗿𝗶𝘃𝗲𝗻 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀. 𝗛𝗼𝘄 𝗱𝗼 𝘆𝗼𝘂 𝘀𝗲𝗲 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗶𝗻 𝘀𝗶𝗹𝗶𝗰𝗼 𝗮𝗻𝗱 𝗶𝗻 𝘃𝗶𝘁𝗿𝗼 𝗺𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗶𝗻𝗴 𝘁𝗿𝗮𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝗶𝗺𝗮𝗹 𝗺𝗼𝗱𝗲𝗹𝘀 𝗶𝗻 𝘁𝗼𝘅𝗶𝗰𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝘁𝗲𝘀𝘁𝗶𝗻𝗴? We welcome your perspectives on how we can navigate the complexities of adopting alternative methodologies. What regulatory frameworks or validation strategies have you found most promising in bridging the gap between innovation and established practices?  👉 𝗬𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗺𝗮𝘁𝘁𝗲𝗿: 𝗦𝗵𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝘁𝗵𝗼𝘂𝗴𝗵𝘁𝘀 𝗮𝗻𝗱 𝗼𝗽𝗶𝗻𝗶𝗼𝗻𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁 𝘀𝗲𝗰𝘁𝗶𝗼𝗻 𝗯𝗲𝗹𝗼𝘄.

📣 𝗦𝘁𝗮𝘆 𝗜𝗻𝗳𝗼𝗿𝗺𝗲𝗱 𝘄𝗶𝘁𝗵 𝗢𝘂𝗿 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿! 📣 This month, we’re bringing you the latest updates on alternatives to animal testing, key policy discussions, and groundbreaking research initiatives. From exciting new podcasts to influential workshops, there’s a lot to explore! 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 🔹 𝗘𝗖𝗛𝗔’𝘀 𝗟𝗮𝘁𝗲𝘀𝘁 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 dives into New Approach Methodologies and their impact on chemical safety. 🔹 𝗡𝗲𝘄 𝗘𝗨 𝗽𝗼𝗹𝗶𝗰𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 on animal testing alternatives. 🔹𝗕𝗲𝘆𝗼𝗻𝗱 𝘁𝗵𝗲 𝗕𝗲𝗮𝗸𝗲𝗿 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 for early-stage researchers. 🔹𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝗧𝗼𝘅’𝘀 𝗿𝗼𝗹𝗲 in the UK’s move towards animal-free safety assessments. 🔹𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗲𝘃𝗲𝗻𝘁𝘀 and opportunities. Want to learn more? 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 𝗵𝗲𝗿𝗲 🔗https://lnkd.in/d3qbve_c #EUPolicy #NAMs #Innovation #Sustainability #AnimalTestingAlternatives #Altertox 

🚨 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗛𝗲𝗮𝗹𝘁𝗵 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲 𝗖𝗮𝗹𝗹 9: 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗳𝗼𝗿 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 🚨  The Innovative Health Initiative (IHI) 𝗖𝗮𝗹𝗹 9 will officially launch in early 2025! 🗓️ 🔍 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗜𝗛𝗜 𝗖𝗮𝗹𝗹 9? This 𝘀𝗶𝗻𝗴𝗹𝗲-𝘀𝘁𝗮𝗴𝗲, 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝗻𝘁-𝗱𝗿𝗶𝘃𝗲𝗻 𝗰𝗮𝗹𝗹 invites you to explore the 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗔𝗴𝗲𝗻𝗱𝗮 (𝗦𝗥𝗜𝗔) and identify untapped opportunities for 𝗽𝘂𝗯𝗹𝗶𝗰-𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 in the healthcare sector. 💼🤝 This is your chance to drive innovation and collaborate on groundbreaking healthcare projects with the support of IHI! 🚀 Applicants are encouraged to align their proposals with the 𝗳𝗶𝘃𝗲 𝗸𝗲𝘆 𝘁𝗼𝗽𝗶𝗰𝘀 set out in the 𝗜𝗛𝗜 𝗦𝗥𝗜𝗔.  🔹 Understanding health determinants and priority disease areas.  🔹 Bringing together stakeholders to develop tools, data, and technologies for better disease prediction, prevention, and management.  🔹 Demonstrating the feasibility of people-centred, integrated healthcare solutions.  🔹 Maximizing the potential of digitalization and data exchange in healthcare. 💻  🔹 Developing new evaluation methodologies to assess the impact of innovative healthcare solutions. 🧑🔬🔬 💡 𝗛𝗼𝘄 𝘁𝗼 𝗚𝗲𝘁 𝗜𝗻𝘃𝗼𝗹𝘃𝗲𝗱: 🔹 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗱𝗿𝗮𝗳𝘁 𝘁𝗼𝗽𝗶𝗰𝘀 📑 and get all the details on the call here 🔗 https://lnkd.in/dD7vnfs6 🔹𝗛𝗮𝘃𝗲 𝗮 𝗽𝗿𝗼𝗷𝗲𝗰𝘁 𝗶𝗱𝗲𝗮? 🧠 Share it on the IHI brokerage platform here 🔗 https://lnkd.in/ev74Viw8  This platform is aimed to facilitate networking and the formation of strong consortia, and will remain open 24/7 until the call deadline. Catch up on the 𝗶𝗻𝗳𝗼 𝘀𝗲𝘀𝘀𝗶𝗼𝗻 recording which provides  🔸 An overview of the 𝘀𝗰𝗼𝗽𝗲 of IHI Call 9 and its 𝗼𝗯𝗷𝗲𝗰𝘁𝗶𝘃𝗲𝘀. 🎯  🔸 A demonstration of how to use the 𝗻𝗲𝘄 𝗯𝗿𝗼𝗸𝗲𝗿𝗮𝗴𝗲 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 to create a personal profile, publish project proposals, and search for potential partners or interesting proposals. 🤝💡 Watch the full session here 🎥 🔗 https://lnkd.in/eYzm8SYc For more information on how you can participate, visit the IHI website 🌐 🔗 https://lnkd.in/e8WrQuU8 #IHI #Innovation #HealthTech #HealthcareInnovation #Research #PublicPrivatePartnership #IHIcall9 #SRIA #HealthcareResearch #EUHealthcare